Considering the greater migratory capacity of tumor PaSCs when compared to normal PaSCs, the reduction in IGFBP-3 levels seems to overweigh the elevation of IGFBP-2, resulting in a net increase in the IGF-1 availability [35]. The gene discussed is IGFBP2; the disease is neoplasm.